https://www.tipranks.com/news/the-fly/intuitive-surgical-price-target-raised-to-622-from-561-at-btig Monte Rosa Therapeutics (GLUE) outlined anticipated 2025 ...
Hosted on MSN1mon
Frana la parete Est del monte Rosa: distacco a 3000 metriPer fortuna è notte e non ci sono persone coinvolte. La parete est del monte Rosa, nel territorio comunale di Macugnana, frana nei giorni successivi a Natale. Detriti sono arrivati anche all ...
Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...
Hosted on MSN2mon
Ai piedi del Monte Rosa aperta una libreria 'ad alta quota'Si chiama 'Il Parnaso del Rosa' e a gestirla è Cornelia Bonardi, libraia di 30 anni nata e cresciuta a Milano ma fin da ragazza legata alla località ai piedi del monte Rosa, dove vive ...
The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock’s upside is ...
BOSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...
“Last year was transformative for Monte Rosa, with significant validation of our capabilities to design and develop ‘only-in-class’ MGDs for previously undruggable targets across a broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback